Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA.
Nat Rev Genet. 2013 Apr;14(4):295-300. doi: 10.1038/nrg3463. Epub 2013 Mar 12.
With the declining cost of sequencing and the ongoing discovery of disease genes, it is now possible to examine hundreds of genes in a single disease-targeted test. Although exome- and genome-sequencing approaches are beginning to compete, disease-targeted testing retains certain advantages and still holds a firm place in the diagnostic evaluation. Here I examine the current state of clinical disease-targeted sequencing and evaluate the benefits and challenges of incorporating sequencing tests into patient care.
随着测序成本的降低和疾病基因的不断发现,现在可以在单次疾病靶向测试中检查数百个基因。尽管外显子组和基因组测序方法开始竞争,但疾病靶向测试仍具有某些优势,在诊断评估中仍然占据着重要地位。本文探讨了临床疾病靶向测序的现状,并评估了将测序测试纳入患者护理中的益处和挑战。